To investigate the immunogenicity of human epidermal growth factor receptor @ ( HER@ ) - positive and triple-negative ( TN ) breast cancers ( BCs ) , we evaluated tumor-infiltrating lymphocytes ( TILs ) and immunologically relevant genes in the neoadjuvant GeparSixto trial .